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Background
In patients who have vascular disease or high-risk diabetes without heart failure, 
angiotensin-converting–enzyme (ACE) inhibitors reduce mortality and morbidity 
from cardiovascular causes, but the role of angiotensin-receptor blockers (ARBs) 
in such patients is unknown. We compared the ACE inhibitor ramipril, the ARB 
telmisartan, and the combination of the two drugs in patients with vascular disease 
or high-risk diabetes.
Methods
After a 3-week, single-blind run-in period, patients underwent double-blind random-
ization, with 8576 assigned to receive 10 mg of ramipril per day, 8542 assigned to 
receive 80 mg of telmisartan per day, and 8502 assigned to receive both drugs (com-
bination therapy). The primary composite outcome was death from cardiovascular 
causes, myocardial infarction, stroke, or hospitalization for heart failure.
Results
Mean blood pressure was lower in both the telmisartan group (a 0.9/0.6 mm Hg 
greater reduction) and the combination-therapy group (a 2.4/1.4 mm Hg greater 
reduction) than in the ramipril group. At a median follow-up of 56 months, the pri-
mary outcome had occurred in 1412 patients in the ramipril group (16.5%), as 
compared with 1423 patients in the telmisartan group (16.7%; relative risk, 1.01; 
95% confidence interval [CI], 0.94 to 1.09). As compared with the ramipril group, 
the telmisartan group had lower rates of cough (1.1% vs. 4.2%, P<0.001) and angio-
edema (0.1% vs. 0.3%, P = 0.01) and a higher rate of hypotensive symptoms (2.6% 
vs. 1.7%, P<0.001); the rate of syncope was the same in the two groups (0.2%). In the 
combination-therapy group, the primary outcome occurred in 1386 patients (16.3%; 
relative risk, 0.99; 95% CI, 0.92 to 1.07); as compared with the ramipril group, there 
was an increased risk of hypotensive symptoms (4.8% vs. 1.7%, P<0.001), syncope 
(0.3% vs. 0.2%, P = 0.03), and renal dysfunction (13.5% vs. 10.2%, P<0.001).
Conclusions
Telmisartan was equivalent to ramipril in patients with vascular disease or high-
risk diabetes and was associated with less angioedema. The combination of the two 
drugs was associated with more adverse events without an increase in benefit. 
(ClinicalTrials.gov number, NCT00153101.)
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Randomized, controlled trials in-volving about 150,000 patients have con-vincingly demonstrated that angiotensin-
converting–enzyme (ACE) inhibitors reduce rates 
of death, myocardial infarction, stroke, and heart 
failure among patients with heart failure,1 left 
ventricular dysfunction,2-4 previous vascular dis-
ease alone,5-7 or high-risk diabetes.8 ACE inhibi-
tors do not block the production of all angioten-
sin II, so direct receptor blockade might be more 
effective. ACE inhibitors reduce bradykinin degra-
dation, which enhances vasodilatation, but in-
crease the rates of angioedema and cough. In pa-
tients with heart failure, angiotensin II levels may 
increase and symptoms worsen, despite the use 
of ACE inhibitors.9 The use of an angiotensin-
receptor blocker (ARB), as compared with placebo, 
reduced the rate of death or hospitalization for 
heart failure in patients with a low ejection frac-
tion and heart failure who either could not toler-
ate an ACE inhibitor10 or were already receiving 
one.11,12 As compared with beta-blockers, ARBs 
also reduced vascular events in high-risk patients 
with hypertension and left ventricular hypertro-
phy.13 Nevertheless, in other high-risk popula-
tions, the role of ARBs as an alternative or in ad-
dition to ACE inhibitors to prevent cardiovascular 
outcomes is not known.
We evaluated whether the ARB telmisartan 
was not inferior to the ACE inhibitor ramipril 
and whether a combination of the two drugs was 
superior to ramipril alone as a treatment to pre-
vent vascular events in high-risk patients who had 
cardiovascular disease or diabetes mellitus but did 
not have heart failure. We used a dose of ramipril 
that had previously been shown to be effective 
for this outcome.
Me thods
Study Design
The design of the study has been described previ-
ously.14 We enrolled patients with coronary, periph-
eral, or cerebrovascular disease or diabetes with 
end-organ damage. Patients who could not toler-
ate ACE inhibitors were randomly assigned to 
receive either telmisartan or placebo in a parallel 
trial.14 Detailed eligibility criteria have also been 
described previously14 (for details, see the Sup-
plementary Appendix, available with the full text 
of this article at www.nejm.org). The primary ob-
jectives of our study were to determine the effec-
tiveness of 80 mg of telmisartan daily, as com-
pared with 10 mg of ramipril daily. If the 
noninferiority of telmisartan was demonstrated, 
we would test the superiority of telmisartan over 
ramipril. We would also determine whether the 
combination of the two drugs was more effective 
than ramipril alone in reducing the composite 
outcome of death from cardiovascular causes, 
myocardial infarction, stroke, or hospitalization 
for heart failure.
The main secondary outcome was a compos-
ite of death from cardiovascular causes, myocar-
dial infarction, or stroke, which was the primary 
outcome in the Heart Outcomes Prevention Evalu-
ation (HOPE) trial.5 Other secondary outcomes 
were new heart failure, diabetes mellitus, atrial 
fibrillation, dementia or cognitive decline, ne-
phropathy, and revascularization procedures. 
Other outcomes were death from any cause or 
from noncardiovascular causes, angina, transient 
ischemic attack, development of left ventricular 
hypertrophy, microvascular complications of di-
abetes, changes in blood pressure or in the ankle-
to-arm ratio of blood pressure, and new cancers.
National coordinators and clinical monitors 
supervised the recruitment of patients at 733 cen-
ters in 40 countries. The trial was coordinated and 
data were gathered and analyzed by the Popula-
tion Health Research Institute at McMaster Uni-
versity and Hamilton Health Sciences, with coor-
dinating suboffices at Oxford University and the 
University of Auckland. The steering committee 
designed and oversaw the trial. An operations 
committee, with representatives from the three 
coordinating centers and the sponsor (Boehringer 
Ingelheim), met regularly to evaluate progress.
All main study outcomes (death according to 
any cause, myocardial infarction, stroke, and hos-
pitalization for heart failure) were adjudicated by 
a central committee whose members were un-
aware of study-group assignments, with the use 
of standard criteria.14 All serious adverse events 
were reviewed by an independent data and safety 
monitoring board.
The initial draft of the manuscript was writ-
ten by Dr. Yusuf and the writing committee, who 
vouch for the data, with input from the steering 
committee. The protocol was approved by regu-
latory authorities and the ethics review commit-
tee at each participating institution.
Run-in Period and Randomization
After written informed consent was obtained, pa-
tients entered a single-blind run-in period in which 
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they received 2.5 mg of ramipril once daily for 
3 days, followed by 40 mg of telmisartan and 2.5 
mg of ramipril once daily for 7 days and then 5 mg 
of ramipril plus 40 mg of telmisartan for 11 to 
18 days. Of the 29,019 patients who entered the 
run-in period, 3399 (11.7%) were excluded from 
the study: 1123 (3.9%) had poor compliance, 597 
(2.1%) withdrew from the study, 492 (1.7%) had 
symptomatic hypotension, 223 (0.8%) had an el-
evated potassium level, 64 (0.2%) had an elevated 
creatinine level, 872 (3.0%) had other reasons for 
exclusion, and 27 (0.1%) died. 
A total of 25,620 patients underwent random-
ization and were stratified according to site with 
the use of permuted blocks through a central auto-
mated telephone service. For the first 2 weeks after 
randomization, 8542 patients were assigned to 
receive 80 mg of telmisartan once daily, 8576 were 
assigned to receive 5 mg of ramipril once daily, 
and 8502 were assigned to receive a combination 
of the two drugs (combination therapy). After 
2 weeks, the dose of ramipril was increased to 
10 mg per day. Follow-up visits occurred at 
6 weeks, at 6 months, and then every 6 months 
until the last scheduled visit.
Interim Analysis and Data Monitoring
An independent data and safety monitoring board 
of cardiologists, statisticians, and clinical-trial ex-
perts met twice yearly; three formal interim anal-
yses were conducted when 25%, 50%, and 75% 
of the events accrued. A modified Haybittle–Peto 
approach15 guided decisions (i.e., a boundary of 
4 SD in the first half of the trial and 3 SD in the 
second half for efficacy; for safety, if boundaries 
of 3 SD and 2 SD, respectively, were crossed in a 
second analysis 4 to 6 months later, it would trig-
ger consideration of stopping).
Statistical Analysis
The number of patients was based on the rate 
of death from cardiovascular causes, myocardi-
al infarction, stroke, or hospitalization for heart 
failure associated with ramipril in the HOPE tri-
al, in which the Kaplan–Meier estimate for the 
primary outcome was 0.0397 per year. A determi-
nation of noninferiority required a hazard ratio 
for telmisartan as compared with ramipril that 
was below a predefined margin, with most of 
ramipril’s effect, as compared with placebo, re-
tained by telmisartan.
The margin was determined by the results of 
the HOPE trial, in which the hazard ratio with 
10 mg of ramipril, as compared with placebo, 
was 0.775 for a composite outcome of death 
from cardiovascular causes, myocardial infarc-
tion, stroke, or hospitalization for heart failure; 
this was similar to the hazard ratios in other 
studies comparing ACE inhibitors with place-
bo.6,7 We chose the 40th percentile (0.794) as a 
more robust reference to describe the effect of 
ramipril. The relative risk was translated into an 
excess risk for placebo as compared with ramipril 
of 1.26. Thus, a margin of 1.13 ensured that telmi-
sartan retained at least half the effect of ramipril, 
if the upper limit of the one-sided 97.5% confi-
dence interval for the hazard ratio was less than 
this value. We also evaluated whether the com-
bination of telmisartan plus ramipril was supe-
rior to ramipril alone.
We tested both hypotheses using group se-
quential tests with a one-sided type I error of 
0.025, with three planned interim analyses. If one 
of the two comparisons did not reject the null 
hypothesis, the other comparison needed an alpha 
of 0.0125. The original planned sample size of 
7800 patients who were followed for a mean of 
4.5 years provided a power of 93% for the supe-
riority hypothesis, if the hazard ratio was 0.87. 
For noninferiority, the expected power was 89%, 
for a hazard ratio of 1.00.
The primary analysis used a time-to-event ap-
proach, counting the first occurrence of any com-
ponent of the composite outcome, and included 
all randomized patients. All reported P values 
(other than for noninferiority) are two-sided. Con-
sistency of treatment effects in prespecified sub-
groups was explored by the Cox regression model, 
with tests for interaction.16,17 We performed a 
sensitivity analysis according to the protocol by 
censoring data from patients who took the study 
drugs for less than 50% of the study period.
R esult s
Characteristics of the Patients
Characteristics of the 25,620 patients who under-
went randomization were similar in the three 
study groups (Table 1); 27% were women, 85% 
had cardiovascular disease, 69% had hyperten-
sion, and 38% had diabetes. A high proportion of 
patients had previously received proven therapies: 
statins (61.6% at baseline, increasing to 70.6% by 
the end of the study), antiplatelet therapy (80.9% 
and 77.5%, respectively), beta-blockers (56.9% and 
56.9%), and diuretics (28.0% and 32.5%).
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Table 1. Baseline Characteristics of the Patients.*
Characteristic
Ramipril  
(N = 8576)
Telmisartan  
(N = 8542)
Combination Therapy 
(N = 8502)
Age — yr 66.4±7.2 66.4±7.1 66.5±7.3
Blood pressure — mm Hg† 141.8±17.4/82.1±10.4 141.7±17.2/82.1±10.4 141.9±17.6/82.1±10.4
Heart rate — beats/min 67.9±12.2 68.0±12.3 67.7±12.2
Body-mass index‡ 28.1±4.5 28.1±4.6 28.0±4.5
Cholesterol — mmol/liter
Total 4.9±1.1 4.9±1.1 5.0±1.2
LDL 2.9±1.0 2.9±1.0 2.9±1.0
HDL 1.3±0.4 1.3±0.4 1.3±0.4
Triglycerides — mmol/liter 1.7±1.1 1.7±1.l 1.7±1.1
Glucose — mmol/liter 6.7±2.6 6.7±2.5 6.7±2.6
Creatinine — µmol/liter 93.5±22.8 93.8±22.8 93.8±22.8
Potassium — mmol/liter 4.4±0.4 4.4±0.4 4.4±0.5
Female sex — no. (%) 2331 (27.2) 2250 (26.3) 2250 (26.5)
Ethnic group — no. (%)§
Asian 1182 (13.8) 1172 (13.7) 1167 (13.7)
Arab 102 (1.2) 106 (1.2) 106 (1.2)
African 206 (2.4) 215 (2.5) 208 (2.4)
European 6273 (73.1) 6213 (72.7) 6222 (73.2)
Native or aboriginal 747 (8.7) 756 (8.9) 728 (8.6)
Other ethnic group 64 (0.7) 77 (0.9) 69 (0.8)
Missing data 2 (<0.1) 3 (<0.1) 2 (<0.1)
Clinical history — no. (%)
Coronary artery disease 6382 (74.4) 6367 (74.5) 6353 (74.7)
Myocardial infarction 4146 (48.3) 4214 (49.3) 4189 (49.3)
Angina pectoris
Stable 3039 (35.4) 2958 (34.6) 2960 (34.8)
Unstable 1257 (14.7) 1296 (15.2) 1264 (14.9)
Stroke or transient ischemic attacks 1805 (21.0) 1758 (20.6) 1779 (20.9)
Peripheral artery disease 1136 (13.2) 1161 (13.6) 1171 (13.8)
Hypertension 5918 (69.0) 5862 (68.6) 5827 (68.5)
Diabetes 3146 (36.7) 3246 (38.0) 3220 (37.9)
Left ventricular hypertrophy 1085 (12.7) 1120 (13.1) 1082 (12.7)
Microalbuminuria¶ 929 (13.1) 923 (13.2) 929 (13.3)
Previous procedures — no. (%)
Coronary-artery bypass grafting 1862 (21.7) 1920 (22.5) 1893 (22.3)
Percutaneous transluminal coronary 
 angioplasty
2527 (29.5) 2476 (29.0) 2434 (28.6)
Smoking status — no. (%)
Current smoker 1062 (12.4) 1062 (12.4) 1101 (12.9)
Past smoker 4463 (52.0) 4468 (52.3) 4345 (51.1)
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Follow-up and Adherence
A total of 25,577 patients (99.8%) were followed 
until a primary event occurred or until the end of 
the study (median, 56 months). Among patients 
in the ramipril group, 92.2% were taking an ACE 
inhibitor and 1.0% were taking an ARB at 1 year, 
with respective proportions of 89.4% and 1.8% at 
2 years, 87.5% and 2.0% at 3 years, 86.6% and 
2.4% at 4 years, and 84.7% and 3.3% at the end 
of the study. Among patients in the telmisartan 
group, 93.9% were taking an ARB and 2.6% were 
taking an ACE inhibitor at 1 year, with respective 
proportions of 91.2% and 4.2% at 2 years, 89.3% 
and 4.6% at 3 years, 87.7% and 5.0% at 4 years, 
and 85.6% and 6.4% at the end of the study. 
Among patients in the combination-therapy group, 
85.5% received both drugs, 2.8% received an ACE 
inhibitor only, and 3.5% received an ARB only at 
1 year; the respective proportions were 81.5%, 
4.2%, and 4.8% at 2 years; 78.7%, 4.5%, and 5.4% 
at 3 years; 76.8%, 4.7%, and 5.7% at 4 years; and 
73.6%, 6.0%, and 6.4% at the end of the study.
The proportion of patients receiving the full 
dose of ramipril at 2 years was 81.7% in the 
ramipril group and 75.3% in the combination-
therapy group. The proportion of patients receiv-
ing the full dose of telmisartan at 2 years was 
88.6% in the telmisartan group and 84.3% in 
the combination-therapy group. The study drug 
was discontinued by 2029 patients (23.7%) in the 
ramipril group and 1796 (21.0%) in the telmisar-
tan group. In the combination-therapy group, 1929 
patients (22.7%) discontinued both drugs, and an 
additional 566 (6.7%) stopped taking one drug.
The most important reasons for permanent 
discontinuation of a study drug are summarized 
in Table 2. More patients discontinued ramipril 
(either as monotherapy or with telmisartan) be-
cause of cough or angioedema than discontinued 
telmisartan alone. In the combination-therapy 
group, an increased number of patients stopped 
taking a study drug because of hypotensive symp-
toms, syncope, diarrhea, or renal impairment, as 
compared with the ramipril groups.
Blood Pressure, Potassium, and Creatinine
Before the run-in period, the mean blood pres-
sure was 141.8/82.1 mm Hg. At 6 weeks, the mean 
blood pressure was reduced by 6.4/4.3 mm Hg in 
the ramipril group, by 7.4/5.0 mm Hg in the tel-
misartan group, and by 9.8/6.3 mm Hg in the 
combination-therapy group. Patients in the telmi-
sartan group and the combination-therapy group 
continued to have slightly lower blood-pressure 
levels throughout the study period (average reduc-
tions, 0.9/0.6 mm Hg and 2.4/1.4 mm Hg, respec-
tively) than did patients in the ramipril group. The 
numbers of patients who had a doubling of the 
creatinine level were similar in the three groups 
(159 in the ramipril group, 170 in the telmisartan 
group, and 180 in the combination-therapy group). 
The numbers of patients who had an increase in 
the potassium level of more than 5.5 mmol per 
liter were similar in the ramipril group (283 pa-
Table 1. (Continued.)
Characteristic
Ramipril  
(N = 8576)
Telmisartan  
(N = 8542)
Combination Therapy 
(N = 8502)
Medication — no. (%)
Statin 5234 (61.0) 5294 (62.0) 5255 (61.8)
Beta-blocker 4847 (56.5) 4860 (56.9) 4876 (57.4)
Aspirin 6473 (75.5) 6469 (75.7) 6461 (76.0)
Clopidogrel or ticlopidine 927 (10.8) 966 (11.3) 931 (11.0)
Antiplatelet agent 6903 (80.5) 6926 (81.1) 6898 (81.1)
Diuretic 2454 (28.6) 2359 (27.6) 2351 (27.7)
Calcium-channel blocker 2821 (32.9) 2787 (32.6) 2864 (33.7)
* Plus–minus values are means ±SD. HDL denotes high-density lipoprotein, and LDL low-density lipoprotein.
† A total of 13,386 patients had a systolic blood pressure of more than 140 mm Hg.
‡ Body-mass index is the weight in kilograms divided by the square of the height in meters.
§ Ethnic group was self-reported. 
¶ The percentage is based on 21,074 patients who underwent baseline urinary analysis: 7073 patients in the ramipril 
group, 7013 patients in the telmisartan group, and 6988 patients in the combination-therapy group. 
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tients) and the telmisartan group (287 patients), 
but the number was significantly higher in the 
combination-therapy group (480 patients, P<0.001 
for the comparison between the combination-
therapy group and the ramipril group).
Primary Outcomes and Death
The primary outcome occurred in 1412 patients 
(16.5%) in the ramipril group, in 1423 patients 
(16.7%) in the telmisartan group, and in 1386 pa-
tients (16.3%) in the combination-therapy group 
(Fig. 1 and 2 and Table 3). The upper boundary of 
the confidence interval (1.09) for the relative risk 
of the primary outcome in the telmisartan group 
as compared with the ramipril group was sig-
nificantly lower than the predefined noninferior-
ity boundary of 1.13 (P = 0.004). However, the 
lower boundary of the confidence interval (0.94) 
indicates that telmisartan was not superior to 
ramipril. The secondary outcome — death from 
cardiovascular causes, myocardial infarction, or 
stroke — occurred in 1210 patients (14.1%) in 
the ramipril group and in 1190 patients (13.9%) 
in the telmisartan group (relative risk, 0.99; 95% 
confidence interval [CI], 0.91 to 1.07; P = 0.001 for 
noninferiority). The results were consistent for 
all components of the primary outcome. Combi-
nation therapy was not significantly better than 
ramipril alone (relative risk, 0.99; 95% CI, 0.92 to 
1.07). Adjustments for the small differences in 
blood pressure did not materially alter the results 
for the primary outcome (relative risk for telmi-
sartan vs. ramipril, 1.02; 95% CI, 0.95 to 1.10; 
relative risk for combination therapy vs. ramipril, 
1.00; 95% CI, 0.93 to 1.07).
There was no significant difference in the to-
tal number of deaths between the ramipril group 
and the telmisartan group (1014 deaths and 989 
deaths, respectively; relative risk in the telmisar-
tan group, 0.98; 95% CI, 0.90 to 1.07); the number 
of deaths was higher in the combination-therapy 
group than in the ramipril group (1065 deaths vs. 
1014 deaths; relative risk in the combination-ther-
apy group, 1.07; 95% CI, 0.98 to 1.16), but the dif-
ference was not siginificant. Analyses of the cause 
of death did not indicate significant differences 
with respect to any particular cause (data not 
shown).
Secondary and Other Outcomes
There were no significant differences in the rates 
of secondary outcomes (Table 4), except for renal 
dysfunction, which occurred in 871 patients (10.2%) 
in the ramipril group, 906 patients (10.6%) in the 
telmisartan group, and 1148 patients (13.5%) in 
the combination-therapy group. As compared with 
the ramipril group, the telmisartan group had a 
similar relative risk of renal impairment (1.04), 
whereas the combination-therapy group had a 
significant increase in the relative risk (1.33, 
Table 2. Discontinuation of Study Medications and Selected Reasons for Permanent Discontinuation.*
Variable
Ramipril 
(N = 8576)
Telmisartan 
(N = 8542)
Combination 
Therapy 
(N = 8502) Telmisartan vs. Ramipril
Combination Therapy  
vs. Ramipril
Relative Risk P Value Relative Risk P Value
number (percent)
Total no. of discontinuations† 2099 (24.5) 1962 (23.0) 2495 (29.3) 0.94 0.02 1.20 <0.001
Reason for permanent discon-
tinuation
Hypotensive symptoms 149 (1.7) 229 (2.7) 406 (4.8) 1.54 <0.001 2.75 <0.001
Syncope 15 (0.2) 19 (0.2) 29 (0.3) 1.27 0.49 1.95 0.03
Cough 360 (4.2) 93 (1.1) 392 (4.6) 0.26 <0.001 1.10 0.19
Diarrhea 12 (0.1) 19 (0.2) 39 (0.5) 1.59 0.20 3.28 <0.001
Angioedema 25 (0.3) 10 (0.1) 18 (0.2) 0.4 0.01 0.73 0.30
Renal impairment 60 (0.7) 68 (0.8) 94 (1.1) 1.14 0.46 1.58 <0.001
* There were no predefined criteria for each of the adverse events listed. Reasons listed are those provided by the investigator for the discon-
tinuation of study drug.
† A patient could have multiple discontinuations, since patients were encouraged to restart study medications whenever possible after discon-
tinuation.
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P<0.001). The rate of renal dialysis was the same 
in the ramipril group and the telmisartan group, 
with 48 patients (0.6%) and 52 patients (0.6%), 
respectively, undergoing dialysis, whereas the rate 
was increased in the combination-therapy group, 
with 65 patients (0.8%) undergoing dialysis (P = 0.10 
for the comparison with the ramipril group).
Subgroup Analyses
Comparisons of key subgroups showed similar 
results between the ramipril group and the telmi-
sartan group (Fig. 3A) and between the ramipril 
group and the combination-therapy group (Fig. 
3B). The results for both comparisons were also 
consistent in analyses that were adjusted for the 
patients’ use of various concomitant drugs (e.g., 
statins, antiplatelet agents, beta-blockers, diuretics, 
and calcium-channel blockers) (data not shown).
Per-Protocol Analysis
For the primary outcome with telmisartan as com-
pared with ramipril, the per-protocol analysis 
showed a relative risk of 1.00 (95% CI, 0.92 to 
1.09; P = 0.006 for noninferiority). Analyses com-
paring combination therapy with ramipril showed 
results similar to those of the intention-to-treat 
analysis (relative risk, 0.98; 95% CI, 0.90 to 1.07).
Discussion
ACE inhibitors have been convincingly shown to 
reduce rates of death, myocardial infarction, 
stroke, heart failure, and revascularization among 
patients with previous cardiovascular disease and 
high-risk diabetes. Therefore, to provide clini-
cally relevant information, trials evaluating ARBs 
in these patients must include proven doses of an 
ACE inhibitor, either as background therapy or as 
a comparator.
In our study, we evaluated both approaches in 
a population similar to the one studied in the 
HOPE trial. Telmisartan was clearly not inferior 
to ramipril for both the prespecified primary out-
come of death from cardiovascular causes, myo-
cardial infarction, stroke, or hospitalization for 
heart failure and for the primary outcome in the 
HOPE trial (death from cardiovascular causes, 
myocardial infarction, or stroke). Similarities in 
the telmisartan group and the ramipril group in 
the proportions of patients who had heart fail-
ure, underwent revascularization, or had renal 
dysfunction (outcomes that were reduced by 
ramipril in the HOPE trial) and the high rates of 
adherence to both drug regimens provided ad-
ditional confidence in establishing the noninfe-
riority of telmisartan. As compared with the 
ramipril group, the telmisartan group had sig-
nificantly fewer episodes of cough or angioede-
ma, but this benefit was partially offset by higher 
rates of hypotensive symptoms (but not syncope). 
Higher rates of hypotension-related symptoms 
are consistent with the slightly lower blood-pres-
sure levels associated with telmisartan, although 
the lower levels did not lead to further benefit. The 
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Figure 2. Relative Risk of the Primary Outcome and of the Main Secondary 
Outcome.
The primary composite outcome was death from cardiovascular causes, 
myocardial infarction, stroke, or hospitalization for heart failure. The main 
secondary outcome was death from cardiovascular causes, myocardial in-
farction, or stroke, which was used as th  primary outcome in the Heart 
Outcomes Prevention Evaluation (HOPE) trial.5 The P value is for the com-
parison with the noninferiority margins. 
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Figure 1. Kaplan–Meier Curves for the Primary Outcome in the Three Study 
Groups.
The composite primary outcome was death from cardiovascular causes, 
myocardial infarction, stroke, or hospitalization for heart failure.
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benefits of ARBs are being evaluated in three 
other placebo-controlled trials that are expected 
to be completed in 2008.14,18,19
Our results parallel the findings of the 
 Valsartan in Acute Myocardial Infarction Trial 
(VALIANT),20 which established the noninferior-
ity of valsartan, as compared with captopril, in 
patients with left ventricular dysfunction or heart 
failure after myocardial infarction. The upper 
boundaries of the confidence intervals and the 
noninferiority margins were almost identical in 
the two studies, even though they enrolled differ-
ent patient populations. The side effects in our 
study were similar to those in the VALIANT study, 
Table 3. Incidence of the Primary Outcome, Its Components, and Death from Any Cause.
Outcome
Ramipril 
(N = 8576)
Telmisartan 
(N = 8542)
Combination Therapy 
(N = 8502)
Telmisartan vs. 
Ramipril
Combination Therapy 
vs. Ramipril
number (percent) risk ratio (95% CI)
Death from cardiovascular causes, myo-
cardial infarction, stroke, or hos-
pitalization for heart failure*
1412 (16.5) 1423 (16.7) 1386 (16.3) 1.01 (0.94–1.09) 0.99 (0.92–1.07)
Death from cardiovascular causes, myo-
cardial infarction, or stroke†
1210 (14.1) 1190 (13.9) 1200 (14.1) 0.99 (0.91–1.07) 1.00 (0.93–1.09)
Myocardial infarction‡ 413 (4.8) 440 (5.2) 438 (5.2) 1.07 (0.94–1.22) 1.08 (0.94–1.23)
Stroke‡ 405 (4.7) 369 (4.3) 373 (4.4) 0.91 (0.79–1.05) 0.93 (0.81–1.07)
Hospitalization for heart failure‡ 354 (4.1) 394 (4.6) 332 (3.9) 1.12 (0.97–1.29) 0.95 (0.82–1.10)
Death from cardiovascular causes 603 (7.0) 598 (7.0) 620 (7.3) 1.00 (0.89–1.12) 1.04 (0.93–1.17)
Death from noncardiovascular causes 411 (4.8) 391 (4.6) 445 (5.2) 0.96 (0.83–1.10) 1.10 (0.96–1.26)
Death from any cause 1014 (11.8) 989 (11.6) 1065 (12.5) 0.98 (0.90–1.07) 1.07 (0.98–1.16)
* Patients could have multiple events in this category. The numbers of events were 2058 (24.0%) in the ramipril group, 2042 (23.9%) in the 
telmisartan group, and 2000 (23.5%) in the combination-therapy group. The differences were not significant (P = 0.83 for telmisartan vs. 
ramipril, and P = 0.38 for combination therapy vs. ramipril).
† This composite was the primary outcome in the Heart Outcomes Prevention Evaluation (HOPE) trial.5
‡ Patients could have multiple events in this category. The category includes both fatal and nonfatal events.
Table 4. Secondary and Other Outcomes.
Outcome
Ramipril 
(N = 8576)
Telmisartan 
(N = 8542)
Combination Therapy 
(N = 8502)
Telmisartan vs.  
Ramipril
Combination Therapy 
vs. Ramipril
number (percent) relative risk (95% CI)
Revascularization 1269 (14.8) 1290 (15.1) 1303 (15.3) 1.03 (0.95–1.11) 1.04 (0.97–1.13)
Hospitalization for angina 925 (10.8) 954 (11.2) 952 (11.2) 1.04 (0.95–1.14) 1.04 (0.95–1.14)
Worsening or new angina 567 (6.6) 536 (6.3) 538 (6.3) 0.95 (0.84–1.07) 0.96 (0.85–1.08)
New diagnosis of diabetes* 366 (6.7) 399 (7.5) 323 (6.1) 1.12 (0.97–1.29) 0.91 (0.78–1.06)
Any heart failure 514 (6.0) 537 (6.3) 478 (5.6) 1.05 (0.93–1.19) 0.94 (0.83–1.07)
New atrial fibrillation† 570 (6.9) 550 (6.7) 537 (6.5) 0.97 (0.86–1.09) 0.96 (0.85–1.07)
Renal impairment‡ 871 (10.2) 906 (10.6) 1148 (13.5) 1.04 (0.96–1.14) 1.33 (1.22–1.44)§
Renal failure requiring dialysis 48 (0.6) 52 (0.6) 65 (0.8) 1.09 (0.74–1.61) 1.37 (0.94–1.98)
* The numbers of patients included in this analysis were 5427 in the ramipril group, 5294 in the telmisartan group, and 5280 in the combina-
tion-therapy group.
† This category includes only patients who did not have atrial fibrillation at baseline: 8296 in the ramipril group, 8259 in the telmisartan 
group, and 8218 in the combination-therapy group.
‡ No specific definitions were used. A determination of renal impairment was based on the clinical investigator’s report of an event that led to 
the discontinuation of a study drug.
§ P<0.001.
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which showed lower rates of cough and angio-
edema in the valsartan group than in the capto-
pril group but higher rates of hypotension-related 
symptoms. There were more dose reductions (but 
not discontinuations) because of renal complica-
tions in the valsartan group than in the captopril 
group, an association that was not observed in 
our study.
In order to establish noninferiority, a rigorous 
trial design is required that includes a patient 
population similar to that in the reference trial, 
a similar drug regimen, high adherence rates, out-
comes that the comparator is known to affect, and 
high statistical power to exclude clinically impor-
tant differences. All these criteria were satisfied 
in our study. The entry criteria for our study and 
the event rates in the ramipril group were simi-
lar to those in the HOPE trial, with high follow-
up rates in both trials. Moreover, the adherence 
rate was higher in the ramipril group (89.4% at 
2 years and 84.7% at the end of the study among 
patients receiving either ramipril or an open-label 
ACE inhibitor) than that in the HOPE trial (85.0% 
and 78.8%, respectively). A sensitivity analysis that 
was restricted to patients who adhered to their 
allocated drug regimen for more than 50% of 
the study period showed the consistency of our 
results and confirmed the robustness of nonin-
feriority.
In our study, we confirmed the statistical 
noninferiority of telmisartan, as compared with 
ramipril, since the upper boundary of the 97.5% 
confidence interval (1.09) was lower than the 
predefined margin of 1.13 for both the primary 
outcome (P = 0.004) and the primary outcome 
used in the HOPE trial (P = 0.001). Telmisartan 
preserved about 95% (95% CI, 83.2 to 106.3) of 
the benefits of ramipril over placebo with respect 
to the primary outcome and preserved 105% 
(95% CI, 91.6 to 119.0) of the benefits with re-
spect to the outcome of death from cardiovascu-
lar causes, myocardial infarction, or stroke that 
were observed in the HOPE trial. Use of the meth-
od of Hasselblad and Kong21 to impute effects of 
telmisartan versus placebo (based on the bene-
fits of ramipril over placebo in the HOPE trial) 
indicates a relative risk of 0.79 (95% CI, 0.70 to 
0.89) for the primary outcome. The number of 
patients who discontinued therapy was signifi-
cantly smaller in the telmisartan group than in 
the ramipril group, although the absolute differ-
ence in the discontinuation rate was modest, be-
cause we used an active run-in phase that selected 
patients for randomization only if they tolerated 
both medications. After randomization, we vig-
orously reinforced adherence and encouraged pa-
tients who stopped medications to restart them. 
In clinical practice, the rates of discontinuation 
might be higher.
We also evaluated whether the combination of 
telmisartan and ramipril (with both drugs target-
ed to the full dose) would be superior to ramipril 
alone. Surprisingly, despite a reduction in systolic 
blood pressure of 2 to 3 mm Hg in the combina-
tion-therapy group, as compared with the ramipril 
group — a decrease that should have translated 
into a risk reduction of 4 to 5% — no significant 
benefit was seen in the primary outcome among 
patients receiving the two-drug therapy. However, 
combination therapy significantly increased the 
risk of hypotension, syncope, renal dysfunction, 
and hyperkalemia, with a trend toward an in-
creased risk of renal dysfunction requiring dialy-
sis. These results are similar to the analysis of the 
combined effects of an ARB and an ACE inhibi-
tor, as compared with an ACE inhibitor alone, in 
four previous trials.22 Therefore, even though com-
bination therapy had a larger biologic effect (as 
suggested by greater blood-pressure lowering and 
changes in potassium), dual blockade did not pro-
duce any additional clinical benefit in this popu-
lation.
In this regard, our results are also similar to 
those of the VALIANT study, in which the com-
bination of a full dose of captopril plus valsartan 
(the latter at a dose of 80 mg per day, which was 
lower than the 160 mg per day used in the val-
sartan-only group) did not significantly reduce 
the occurrence of the primary outcome but did 
increase hypotension.20 Taken together, these two 
studies showed no additive effect for an ARB in 
conjunction with a full dose of a proven ACE in-
hibitor.
However, our findings contrast with those of 
two other studies. In the Candesartan in Heart 
Failure: Assessment of Reduction in Mortality and 
Morbidity (CHARM) study,12 which involved pa-
tients who had symptomatic heart failure and had 
been hospitalized in the previous 6 months, can-
desartan, when added to existing therapy with 
any ACE inhibitor used at variable doses (with less 
than half the patients receiving full doses), was 
superior to placebo in reducing death or hospi-
talization for heart failure. Similarly, a reduction 
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in hospitalization for heart failure was observed 
in the Valsartan Heart Failure Trial,11 which com-
pared valsartan with placebo in patients with 
heart failure, with about 90% of patients receiv-
ing background therapy with ACE inhibitors at 
variable doses. Both trials differed from both our 
study and the VALIANT study in that decisions 
regarding the dose and choice of an ACE inhibi-
tor were left to individual physicians, and there 
was no attempt to titrate the ACE inhibitor to the 
maximum dose. Furthermore, patients had symp-
tomatic heart failure despite receiving an ACE in-
hibitor.
The lack of an additional benefit of a substan-
tial lowering of blood pressure is puzzling, both 
in our study and in the VALIANT study. These 
results may have been due to previous successful 
treatment of patients with other drugs so that 
little further clinical benefit was possible with 
the addition of full doses of multiple drugs that 
block the renin–angiotensin system. Alternatively, 
some harm from combined therapy with ACE in-
hibitors and ARBs used at full doses may offset 
any potential gains. Further information is ex-
pected regarding the role of ARBs as compared 
with placebo in patients after stroke,18 in high-
risk patients with vascular disease who are un-
able to tolerate an ACE inhibitor,14 and in pa-
tients with atrial fibrillation.19
In conclusion, our data show that in patients 
who have vascular disease or high-risk diabetes 
but do not have heart failure, telmisartan is an 
equally effective alternative to ramipril and is less 
likely to cause angioedema. The choice between 
the two agents will depend on the preferences of 
patients and physicians and the individual patient’s 
susceptibility to specific adverse events. There is 
no additional advantage (and there is some harm) 
from the combination of telmisartan and ramipril 
used in full doses in this population, as compared 
with ramipril alone.
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Figure 3 (facing page). Relative Risks in Prespecified 
Subgroups.
Shown are the comparisons between the telmisartan 
group and the ramipril group (Panel A) and between 
the combination-therapy (telmisartan plus ramipril) 
group and the ramipril group (Panel B). The risk score 
from the Heart Outcomes Prevention Evaluation 
(HOPE) trial5 ranges from 2.350 to 5.928, with higher 
scores indicating higher risk. The sizes of the squares 
are proportioned to the numbers of events. 
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